Trials / Terminated
TerminatedNCT03137758
A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Pellficure Pharmaceuticals, Inc · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, non-randomized, Phase I, dose escalation/dose expansion study of PCUR-101 in combination with androgen suppression therapy in the patients with metastatic CRPC
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PCUR - 101 | PCUR-101 Capsules 25 mg are solid dosage forms for oral administration |
Timeline
- Start date
- 2017-07-24
- Primary completion
- 2019-04-03
- Completion
- 2019-09-17
- First posted
- 2017-05-03
- Last updated
- 2020-03-09
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03137758. Inclusion in this directory is not an endorsement.